Aktis Oncology (AKTS) vs Savara (SVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Savara is the larger company by market cap ($992.4 million vs $986.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTS | SVRA |
|---|---|---|
| Share price | $17.74 | $4.83 |
| Market cap | $986.69M | $992.37M |
| 1-day change | -1.44% | -1.02% |
| YTD return | — | -19.90% |
| 1-year return | — | +39.19% |
| 5-year return | — | +278.29% |
| EPS (TTM) | $-1.70 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.19 | $7.01 |
| 52-week low | $14.72 | $3.35 |
| Distance from 52-week high | -48.11% | -31.05% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +99.49% | +128.99% |
| Average volume | 366.06K | 1.83M |
| Shares outstanding | 53.75M | 205.46M |
| Employees | 79 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aktis Oncology
AKTS stock →Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About Savara
SVRA stock →Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
AKTS vs SVRA FAQ
Which is bigger, Aktis Oncology or Savara?
Savara (SVRA) is larger, with a market capitalization of $992.37M compared with $986.69M for Aktis Oncology (AKTS).
Are Aktis Oncology and Savara in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.